• Explore /
  • Poster
  • / A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).

A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).

Abstract Poster

Authors

null

Gabriela Liliana Bravo Montenegro

Urologic Oncology Branch. National Cancer Institute of the National Institutes of Health, Bethesda, MD

Gabriela Liliana Bravo Montenegro , Elad Sharon , Cheryl Ann Pickett-Gies , Lisa Mac , Julia C. Friend , Erin Purcell , Srivandana Akshintala , John Glod , Rana R. McKay , Mehmet Asim Bilen , Alexis Rompre-Brodeur , Brad Webster , Nikhil Gopal , Ashkan A. Malayeri , Maria Merino , Zachary Kozel , Sandeep Gurram , W. Marston Linehan , Ramaprasad Srinivasan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT04981509

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4604)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4604

Abstract #

TPS4604

Poster Bd #

92a

Abstract Disclosures

Similar Posters

First Author: Arjun Vasant Balar

First Author: Rana R. McKay

First Author: Dale Randall Shepard

First Author: Joshua E. Reuss